Tags

Type your tag names separated by a space and hit enter

Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults.
J Travel Med. 2015 Jan-Feb; 22(1):48-56.JT

Abstract

BACKGROUND

Compact and short pre-travel immunization schedules, which include several vaccinations in a single visit, are desirable for many travelers. However, concomitant vaccination could potentially compromise immunogenicity and/or safety of the individual vaccines and, therefore, possible vaccine interferences should be carefully assessed. This article discusses the immunogenicity and safety of travel vaccines for typhoid fever (TF) and yellow fever (YF), when administered with or without a quadrivalent meningococcal glycoconjugate ACWY-CRM vaccine (MenACWY-CRM).

METHODS

Healthy adults (18-≤60 years) were randomized to one of three vaccine regimens: TF + YF + MenACWY-CRM (group I; n = 100), TF + YF (group II; n = 101), or MenACWY-CRM (group III; n = 100). Immunogenicity at baseline and 4 weeks post-vaccination (day 29) was assessed by serum bactericidal assay using human complement (hSBA), enzyme-linked immunosorbent assay (ELISA), or a neutralization test. Adverse events (AEs) and serious adverse events (SAEs) were collected throughout the study period.

RESULTS

Non-inferiority of post-vaccination geometric mean concentrations (GMCs) and geometric mean titers (GMTs) was established for TF and YF vaccines, respectively, when given concomitantly with MenACWY-CRM vaccine versus when given alone. The percentages of subjects with seroprotective neutralizing titers against YF on day 29 were similar in groups I and II. The antibody responses to meningococcal serogroups A, C, W-135, and Y were within the same range when MenACWY-CRM was given separately or together with TF and YF vaccines. The percentage of subjects reporting AEs was the same for TF and YF vaccines with or without MenACWY-CRM vaccine. There were no reports of SAEs or AEs leading to study withdrawals.

CONCLUSIONS

These data provide evidence that MenACWY-CRM can be administered with typhoid Vi polysaccharide vaccine and live attenuated YF vaccine without compromising antibody responses stimulated by the individual vaccines. MenACWY-CRM can, therefore, be incorporated into travelers' vaccination programs without necessitating an additional clinic visit (NCT01466387).

Authors+Show Affiliations

Department of Infectious Diseases and Tropical Medicine, University of Munich, Munich, Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

25308927

Citation

Alberer, Martin, et al. "Safety and Immunogenicity of Typhoid Fever and Yellow Fever Vaccines when Administered Concomitantly With Quadrivalent Meningococcal ACWY Glycoconjugate Vaccine in Healthy Adults." Journal of Travel Medicine, vol. 22, no. 1, 2015, pp. 48-56.
Alberer M, Burchard G, Jelinek T, et al. Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults. J Travel Med. 2015;22(1):48-56.
Alberer, M., Burchard, G., Jelinek, T., Reisinger, E., Beran, J., Hlavata, L. C., Forleo-Neto, E., Dagnew, A. F., & Arora, A. K. (2015). Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults. Journal of Travel Medicine, 22(1), 48-56. https://doi.org/10.1111/jtm.12164
Alberer M, et al. Safety and Immunogenicity of Typhoid Fever and Yellow Fever Vaccines when Administered Concomitantly With Quadrivalent Meningococcal ACWY Glycoconjugate Vaccine in Healthy Adults. J Travel Med. 2015 Jan-Feb;22(1):48-56. PubMed PMID: 25308927.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults. AU - Alberer,Martin, AU - Burchard,Gerd, AU - Jelinek,Tomas, AU - Reisinger,Emil, AU - Beran,Jiri, AU - Hlavata,Lucie Cerna, AU - Forleo-Neto,Eduardo, AU - Dagnew,Alemnew F, AU - Arora,Ashwani K, Y1 - 2014/10/13/ PY - 2014/03/24/received PY - 2014/06/26/revised PY - 2014/07/21/accepted PY - 2014/10/14/entrez PY - 2014/10/14/pubmed PY - 2015/9/15/medline SP - 48 EP - 56 JF - Journal of travel medicine JO - J Travel Med VL - 22 IS - 1 N2 - BACKGROUND: Compact and short pre-travel immunization schedules, which include several vaccinations in a single visit, are desirable for many travelers. However, concomitant vaccination could potentially compromise immunogenicity and/or safety of the individual vaccines and, therefore, possible vaccine interferences should be carefully assessed. This article discusses the immunogenicity and safety of travel vaccines for typhoid fever (TF) and yellow fever (YF), when administered with or without a quadrivalent meningococcal glycoconjugate ACWY-CRM vaccine (MenACWY-CRM). METHODS: Healthy adults (18-≤60 years) were randomized to one of three vaccine regimens: TF + YF + MenACWY-CRM (group I; n = 100), TF + YF (group II; n = 101), or MenACWY-CRM (group III; n = 100). Immunogenicity at baseline and 4 weeks post-vaccination (day 29) was assessed by serum bactericidal assay using human complement (hSBA), enzyme-linked immunosorbent assay (ELISA), or a neutralization test. Adverse events (AEs) and serious adverse events (SAEs) were collected throughout the study period. RESULTS: Non-inferiority of post-vaccination geometric mean concentrations (GMCs) and geometric mean titers (GMTs) was established for TF and YF vaccines, respectively, when given concomitantly with MenACWY-CRM vaccine versus when given alone. The percentages of subjects with seroprotective neutralizing titers against YF on day 29 were similar in groups I and II. The antibody responses to meningococcal serogroups A, C, W-135, and Y were within the same range when MenACWY-CRM was given separately or together with TF and YF vaccines. The percentage of subjects reporting AEs was the same for TF and YF vaccines with or without MenACWY-CRM vaccine. There were no reports of SAEs or AEs leading to study withdrawals. CONCLUSIONS: These data provide evidence that MenACWY-CRM can be administered with typhoid Vi polysaccharide vaccine and live attenuated YF vaccine without compromising antibody responses stimulated by the individual vaccines. MenACWY-CRM can, therefore, be incorporated into travelers' vaccination programs without necessitating an additional clinic visit (NCT01466387). SN - 1708-8305 UR - https://www.unboundmedicine.com/medline/citation/25308927/Safety_and_immunogenicity_of_typhoid_fever_and_yellow_fever_vaccines_when_administered_concomitantly_with_quadrivalent_meningococcal_ACWY_glycoconjugate_vaccine_in_healthy_adults_ DB - PRIME DP - Unbound Medicine ER -